The primary therapeutic role is in supporting the management of symptoms that interfere with daily functioning related to bladder overactivity. Solifenacin succinate is commonly used for managing specific bladder conditions.

The medicine is used to address the core symptom cluster of Overactive Bladder Syndrome (OAB) in adults, including urinary urgency, abnormally frequent urination, and urge urinary incontinence. It is also relevant in specific pediatric patient groups for the symptomatic management of Neurogenic Detrusor Overactivity (NDO). This supportive therapy is applied in clinical settings where long-term management of chronic and disruptive voiding patterns is appropriate.

Supportive therapy is relevant for easing symptoms that may interfere with functional stability and overall comfort. By supporting an improvement in comfort during symptomatic periods, the medication helps reduce the number of daily and nocturnal voiding episodes, assists with maintaining functional stability, and contributes to easing the overall symptom load.

---

Quick Fact: Relief for Urgency and Frequency

The primary benefit is in supporting a decrease in the sudden, compelling urinary urgency and the resulting need for frequent urination. This assists with maintaining functional stability during symptomatic periods.

Eligibility and Contraindications for Везикар (Solifenacin)

Везикар (solifenacin) is subject to strict eligibility rules documented in official government regulatory information.

Populations for Whom Use is Contraindicated (Must Not Use):

The medicine is formally contraindicated and must not be used by patients who have certain pre-existing conditions:

• Urinary Retention (inability to empty the bladder).
• Gastric Retention or severe gastrointestinal conditions (including toxic megacolon, ileus).
• Uncontrolled Narrow-Angle Glaucoma.
• Known Hypersensitivity to solifenacin succinate or any of the product's components.
• Severe Hepatic Impairment (Child-Pugh C).
• Patients undergoing Haemodialysis.

Restricted or Cautionary Use Populations (Special Consideration Required):

Population	Regulatory Restriction (Official Labeling)
Severe Renal Impairment (CrCl le 30 mL/ min)	Use with caution. Maximum dose is limited to 5 mg daily.
Moderate Hepatic Impairment (Child-Pugh B)	Use with caution. Maximum dose is limited to 5 mg daily.
Co-administration with CYP3A4 Inhibitors	Maximum dose must not exceed 5 mg daily when taken with potent CYP3A4 inhibitors (e.g., ketoconazole).
Combination Restriction	Contraindicated if severe renal or moderate hepatic impairment is present and a potent CYP3A4 inhibitor is taken concomitantly.

Age and Pregnancy Status:

The tablet form is generally established for use in Adults. An oral suspension formulation is specifically approved for pediatric patients ge 2 years of age for certain conditions. Safety and effectiveness are not established for children younger than 2 years of age. Official labeling advises caution regarding use during Pregnancy and Lactation.

Interactions with other medicines and products

Везикар (Solifenacin) may interact with other medicinal products primarily through its metabolism and anticholinergic activity, as documented in official regulatory labeling.

Pharmacokinetic Interactions

Solifenacin is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with potent CYP3A4 inhibitors, such as ketoconazole, significantly increases the systemic exposure (AUC) of solifenacin. Therefore, a maximum dose restriction is required; the dose must not exceed 5 mg per day when taken concurrently with a potent CYP3A4 inhibitor. This restriction also applies to patients with severe kidney or moderate liver impairment who are taking such inhibitors.

Pharmacodynamic Interactions

Interacting Product Category	Effect of Interaction
Anticholinergic Agents	Additive therapeutic and side effects; simultaneous use is generally discouraged.
Cholinergic Receptor Agonists	Reduced therapeutic effect of solifenacin due to opposing mechanisms.
Medicinal Products Stimulating GI Motility (e.g., metoclopramide)	Solifenacin may reduce the effect of these products.

Official labeling indicates that co-administration does not result in clinically significant changes to the plasma concentrations of combined oral contraceptives (ethinyl estradiol/levonorgestrel), warfarin, or digoxin. Following discontinuation of solifenacin, a period of approximately one week should be allowed before commencing other anticholinergic therapy.

The action of Vesicar (Solifenacin) is defined by its influence on the parasympathetic nervous system and the control of smooth muscle tone within the urinary bladder. The entire mechanism follows a precise molecular cascade that leads directly to a change in the organ's function.

M3 Receptor Competitive Blockade

Solifenacin acts as a competitive antagonist primarily targeting the M3 muscarinic acetylcholine receptor (M3 receptor) located on the detrusor smooth muscle. By binding reversibly to this receptor, the drug suppresses the transmission signal carried by the neurotransmitter acetylcholine. This targeted molecular blockade interrupts the pathway responsible for initiating muscle contraction.

Detrusor Muscle Relaxation and Filling Volume

The molecular blockade translates directly into an antispasmodic effect, causing the detrusor muscle to relax and attenuating the potential for acetylcholine-mediated contraction. This physiological change increases the volume accommodation during the storage phase of the bladder. The mechanism results in an increase in intravesical volume by suppressing the involuntary contraction signaling driven by the M3 receptor. This mechanism operates primarily in the periphery, directly modulating the physiological response of the target organ.

Везикар (solifenacin) is administered orally once daily for symptomatic management, following a high-level titration regimen. For adults, the medicine is supplied as 5 mg and 10 mg film-coated tablets. The standard adult dosing begins at 5 mg once daily. The dosage may be increased to a maximum of 10 mg once daily, based on the individual's response and tolerability to the starting dose.

Administration can occur with or without food. The tablets must be swallowed whole with liquid and should not be crushed, broken, or chewed. This ensures the correct delivery properties are maintained. The medicine is also available as a 1 mg/mL oral suspension for pediatric patients (aged 2 years and older) managing Neurogenic Detrusor Overactivity; the dosing for this suspension is weight-based. If a dose of the oral suspension is missed, it should be skipped if more than 12 hours have passed, and the next dose should be taken at the usual time.

Official instructions mandate specific dose restrictions in populations with impaired function or concurrent medication use. The daily dose must not exceed 5 mg for patients with severe renal impairment (creatinine clearance leq 30 mL/min) or moderate hepatic impairment (Child-Pugh B). The 5 mg maximum also applies when the medicine is co-administered with strong CYP3A4 inhibitors. Use is not recommended in patients with severe hepatic impairment (Child-Pugh C).

Research Evidence / Overview of Studies for Везикар

This overview summarizes the formal clinical research and studies conducted for Solifenacin succinate, describing the types of evidence that exist and the clinical areas that have been studied, without providing individual medical advice or treatment recommendations.

Evidence for use in Overactive Bladder (OAB) Syndrome

The primary research base for the clinical evaluation of this medicine in adults with Overactive Bladder (OAB) syndrome is derived primarily from short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies were applied to adult populations experiencing fluctuating or unstable symptoms like urgency, abnormal frequency of urination, and urge urinary incontinence.

Studies examined outcomes related to functional patterns, including measurements of micturition frequency and the number of urge urinary incontinence episodes. Research describes the data patterns that were observed across these short-term studies, where measurements were typically recorded over a period of 12 weeks. Additionally, studies monitored patient-reported outcomes describing perceived discomfort and any change in their health-related quality of life.

Evidence for use in Neurogenic Detrusor Overactivity (NDO)

Research exploring Solifenacin in the context of Neurogenic Detrusor Overactivity (NDO) was conducted in specialized populations, including both adults and pediatric patients whose bladder dysfunction is linked to a neurological condition. These studies employed objective measures to monitor functional bladder parameters.

Specifically, clinical studies examined how the medicine was associated with changes in Maximum Cystometric Capacity (MCC) and Bladder Compliance. Research describes that changes in these urodynamic variables were the focus of observation during the study period. Research also monitored outcomes related to episodic or acute changes, specifically the number of incontinence episodes.

Long-Term Research and Durability of Study Findings

To gather data on outcomes over extended time, researchers conducted long-term open-label extension studies. These extensions follow patients for longer defined time intervals, often up to a year or more. Findings from these non-comparative long-term studies provide context on how symptoms evolved in the observed populations. However, because these extension studies lack a placebo or active comparison group during the long-term phase, the research provides limited comparative data on outcomes over extended time. This research provides insight into the evolution of outcomes over a longer duration, but the findings describe group patterns, not personal outcomes.

Evidence in Specialized Populations

The research has included evaluation in specific populations where evidence was needed for regulatory purposes. Solifenacin was evaluated in pediatric subjects (children 2 years and older) with NDO. Studies explored these groups using dose-titration designs and monitored functional bladder parameters.

Furthermore, studies also monitored the pharmacokinetic patterns (how the body processes the medicine) in patients with varying degrees of renal or hepatic impairment. The results apply only to the populations studied, and data are still emerging for certain degrees of impairment.

What is Still Uncertain in the Research Record

While a substantial body of evidence exists from controlled studies, certain research limitations and gaps remain. There is limited information for long-term outcomes beyond approximately one year, as the primary source of this data is from open-label follow-up, not controlled long-term trials. Comparative evidence is lacking against every other available treatment option, requiring indirect analysis to understand the broader evidence landscape. Evidence in the youngest pediatric subjects (e.g., children aged 2 to 5 years) remains limited to smaller groups within the overall population studied. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Common questions about Везикар (FAQ)

Q: Can Везикар be used for problems other than an overactive bladder?

Official regulatory documents state that the medicine is indicated for the treatment of Overactive Bladder (OAB) symptoms. Additionally, in some formulations and populations, it is indicated for Neurogenic Detrusor Overactivity (NDO). Approved uses are defined in regulatory documents for the treatment of these specific conditions.

---

Q: What does the official product information say about taking Везикар with alcohol?

Official guidance advises caution with alcohol while using this medicine. This is because alcohol consumption may increase the risk of central nervous system side effects, such as dizziness or somnolence (drowsiness). The official guidance advises caution with alcohol.

---

Q: Does taking Везикар affect my ability to drive?

The official product label states that the medicine may cause side effects such as blurred vision and somnolence (drowsiness). The official label contains warnings for patients to exercise caution when driving or operating machinery due to these potential side effects.

---

Q: Are there any foods or drinks to avoid while using Везикар?

According to the official instructions, the tablets can be taken with or without food. Regulatory documents do not contain specific warnings prohibiting the consumption of particular foods or non-alcoholic drinks.

---

Q: What should I do if I miss a dose of Везикар?

Regulatory instructions for the tablet formulation indicate that a missed dose is generally skipped. The next dose is then taken at the regular time the following day. Two doses should not be taken on the same day.

---

Q: Does Везикар interact with medicines for high blood pressure?

Official drug information identifies potential interactions primarily related to the medicine's metabolism and its general antimuscarinic activity. Regulatory information notes the importance of informing a healthcare provider of all current medications, including those for high blood pressure, due to the risk of additive side effects or other potential drug interactions.

---

Q: Does taking Везикар affect sleep or cause insomnia?

Insomnia (difficulty sleeping) is listed in the official documents as a Common side effect (occurring in 1% to 10% of patients). Conversely, the official label also indicates that somnolence (drowsiness) has been reported by some patients.

---

Q: Does Везикар affect other smooth muscles in the body?

While the medicine's primary action targets the detrusor (bladder) smooth muscle, its systemic effects may affect other smooth muscles in the body. This is indirectly suggested by common side effects like constipation and warnings against use in patients with conditions such as gastric retention.

---

Q: Is it important to stay hydrated while taking Везикар?

Due to the very common side effect of dry mouth, maintaining adequate fluid intake is generally important. Official warnings related to dry mouth and decreased sweating suggest that managing fluid balance is an important consideration.

---

Q: What is the longest period a person usually takes Везикар?

The clinical trials that supported initial regulatory approval typically studied patients over a period of 12 weeks. However, to gather long-term data, official research documents describe patients continuing the use of the medicine in non-comparative open-label extension studies for periods up to one year or longer.

---

Q: Is Везикар addictive?

The medicine is not classified as a controlled substance by regulatory agencies. Official drug information does not contain statements regarding abuse or addiction potential.

---

Q: Is Везикар available without a prescription in some countries?

The medicine is officially classified as a prescription-only medicine in the countries where it is approved by regulatory bodies. This means a valid prescription from a licensed healthcare provider is required for dispensing.

---

Q: Does Везикар cause weight gain?

Based on the official list of adverse reactions reported during clinical trials, weight gain is not categorized as a common or very common side effect associated with this medicine.

---

Q: Is it common for people to feel dizzy when first starting Везикар?

Dizziness is listed in official documents as a Less Common adverse reaction. This means it was reported to occur in a minority of patients, specifically 1% to 10% of those participating in clinical trials.

---

Q: Are there long-term studies on the safety of Везикар?

Yes, official regulatory documents reference long-term open-label extension studies. These studies followed patients for periods up to one year or more to continue monitoring efficacy and collect extended safety data on the medicine.

---

Q: Can Везикар be used by children?

The oral suspension formulation is approved by regulatory bodies for use in pediatric patients aged 2 years and older specifically for the treatment of Neurogenic Detrusor Overactivity (NDO). The tablet formulation is generally indicated for use in adults.

---

Q: Is the research evidence for Везикар based mainly on short-term trials?

Regulatory summaries confirm that the primary data supporting effectiveness for Overactive Bladder (OAB) comes from short-term (typically 12-week), randomized, placebo-controlled trials. However, open-label extension studies provide additional data over longer periods.

---

Q: Are generic versions of the active ingredient in Везикар available?

Yes, the active ingredient in Везикар, solifenacin succinate, is officially available in several generic formulations. These generic versions are approved by the relevant regulatory authorities.

---

Q: What are the official recommendations regarding sun exposure while taking Везикар?

Official warnings indicate the medicine may cause the body to sweat less, which increases the risk of heat prostration (overheating) in hot environments or during strenuous activity. This suggests the need for caution in conditions, such as sun exposure, where overheating is a risk.

---

Q: Does Везикар need to be stored in a special way?

Yes, regulatory labeling defines specific storage requirements to maintain product quality. Tablets should be kept at Controlled Room Temperature. The liquid oral suspension requires specific handling and must be discarded 28 days after first opening.

---

Q: Is Везикар used to treat stress incontinence?

Official indications for the medicine are restricted to treating the symptoms of Overactive Bladder (OAB). This includes symptoms like urgency, frequency, and urge urinary incontinence. It is not formally indicated for the treatment of stress urinary incontinence.

---

Q: What does the drug label say about how Везикар is removed from the body?

Official product information contains a detailed section on pharmacokinetics, which describes how the body metabolizes and eliminates the medicine. This includes technical data on the drug's half-life and its routes of elimination via both urine and feces.

---

Q: How long does the effect of one dose of Везикар last?

The medicine is approved to be taken once daily. This dosing schedule reflects its formulation, which is designed to provide a sustained therapeutic effect across a 24-hour period.

---

Q: How often do people using Везикар report headaches?

Headache is listed in the official adverse reactions documentation, categorized as a Rare side effect. This means the event occurred infrequently, specifically in less than 1% of patients in the clinical trial data.

---

Q: Do studies suggest any difference in Везикар's effect based on age or gender?

Studies have been conducted to compare how the medicine is processed in elderly versus younger adults. The differences found in drug processing between groups were described as small and official data suggests no clear effect of gender on the medicine’s processing.

---

Q: What is the purpose of the 'extended-release' formulation of the drug?

The formulation is designed to release the active ingredient slowly and continuously. This design allows for consistent drug levels in the body over a sustained period, enabling the medicine to be taken effectively on a once-daily basis.

---

Q: Is Везикар suitable for older adults?

The medicine is generally established for use in adults, which includes older adults. Clinical studies described similar patterns of safety and effectiveness between younger and older adult patient groups.

The storage and disposal instructions for VESIcare (solifenacin succinate) are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Conditions

Formulation	Required Storage Temperature	In-Use Stability Constraint
Tablets	Controlled Room Temperature (25 C / 77 F); permitted excursions 15 C to 30 C	Not Applicable
Oral Suspension	Unopened: 20 C to 25 C	Discard 28 days after first opening

The oral suspension bottle must be kept tightly closed. All formulations must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal

Official disposal guidance recommends that solifenacin succinate tablets be flushed down the toilet if a drug take-back program is not available. Unused or expired product must be discarded according to local regulations to minimize environmental contamination.